Tki Treatment Discontinuation: How Many Patients Could Stop Tyrosine Kinase Treatment According To Discontinuation Trials Criteria? Incidence And Prognostic Impact Of Deep Molecular Response In A Cohort Of Chronic Myeloid Leukemia Patients Of South Brazil'S Hematology Centers

Sustained deep molecular response (MR4.5) after imatinib treatment defines a subgroup of patients with chronic myeloid leukemia (CML) with better outcome and that probably would be able to stop treatment in the future, according to results of clinical TKI discontinuation trials. Most of these trials showed that patients with a long-term imatinib treatment and low Sokal risk have a higher probability of maintain a deep molecular remission after stopping treatment.